8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 21, 2026·SEC
Material company update
Apr 7, 2026·SEC
Aimei Health Technology Co., Ltd(AFJK)Earnings, Financials & Key Ratios
AFJK•NASDAQ•Banking & Credit
$42.68
$261M mkt cap·251.0× P/E·Price updated May 7, 2026
SectorFinancial ServicesIndustrySPACs & Shell CompaniesSub-IndustryHealthcare and life sciences SPACs
AboutAimei Health Technology Co., Ltd does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. It intends to acquires businesses in the biopharmaceutical, medical technology/device industries or diagnostic, and other services sectors. Aimei Health Technology Co., Ltd was incorporated in 2023 and is based in New York, New York.Show more
- Net Interest Income$0-100.0%
- Total Revenue$0
- Net Income$1M-58.5%
- Return on Equity2.64%-26.6%
- Net Interest Margin0%-100.0%
- ROA2.47%-30.3%
- Equity / Assets66.44%-32.2%
- Book Value per Share1.99-75.2%
- Tangible BV/Share1.99-75.2%
- Debt/Equity0.25+7893.2%
AFJK Key Insights
Aimei Health Technology Co., Ltd (AFJK) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 97 (top 3%)
- ✓Well capitalized: 66.4% equity/assets
- ✓Share count reduced 55.2% through buybacks
✗Weaknesses
- ✗Weak 3Y average ROE of 2.2%
- ✗Weak Piotroski F-Score: 2/9
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 21.5x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
AFJK Price & Volume
Aimei Health Technology Co., Ltd (AFJK) stock price & volume — 10-year historical chart
Loading chart...
AFJK Growth Metrics
Aimei Health Technology Co., Ltd (AFJK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-58.48%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-39.89%
Return on Capital
10 Years-1.19%
5 Years-1.19%
3 Years-1.19%
Last Year-2.05%
AFJK Recent Earnings
Aimei Health Technology Co., Ltd (AFJK) EPS & revenue vs analyst estimates — last 4 quarters
Q2 2026Latest
May 4, 2026EPS
$0.02
Revenue
—
Q2 2026
Apr 3, 2026EPS
$0.05
Revenue
—
Q4 2025
Nov 18, 2025EPS
$0.06
Revenue
—
Q3 2025
Aug 13, 2025EPS
$0.07
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.02 | — |
| Q2 2026 | Apr 3, 2026 | $0.05 | — |
| Q4 2025 | Nov 18, 2025 | $0.06 | — |
| Q3 2025 | Aug 13, 2025 | $0.07 | — |
Based on last 10 quarters of dataView full earnings history →
AFJK Peer Comparison
Aimei Health Technology Co., Ltd (AFJK) competitors in Healthcare and life sciences SPACs — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CANG | 250.04M | 0.54 | 5.66 | -52.73% | -5.15% | -4.06% | 0.04 | |
 BTBT | 589.49M | 1.83 | 9.15 | 264.59% | 21.41% | 0.03 | ||
 CLOV | 1.44B | 2.82 | -16.59 | 40.34% | -2.58% | -17.08% | ||
 ACMR | 3.92B | 59.20 | 43.21 | 15.24% | 10.44% | 6.11% | 0.16 | |
 GDRX | 973.26M | 2.84 | 33.29 | 0.57% | 3.74% | 4.75% | 0.10 | |
 HIMS | 6.63B | 25.67 | 50.32 | 59% | 5.47% | 23.73% | 2.07 | |
 TDOC | 1.26B | 6.96 | -6.11 | -1.54% | -6.81% | -12.37% | 0.75 | |
 AMWL | 129.49M | 7.75 | -1.30 | -1.98% | -48.16% | -33.48% | 0.02 |
Compare AFJK vs Peers
Aimei Health Technology Co., Ltd (AFJK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AFJK Income Statement
Aimei Health Technology Co., Ltd (AFJK) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|
| Net Interest Income | 199.85K | 3.62M | 0 |
| NII Growth % | - | 1709.88% | -100% |
| Net Interest Margin % | 0.28% | 4.9% | 0% |
| Interest Income | 199.85K | 3.62M | 0 |
| Interest Expense | 0 | 0 | 0 |
| Loan Loss Provision | 0 | 0 | 0 |
| Non-Interest Income | -199.85K | -3.62M | 0 |
| Non-Interest Income % | - | - | - |
| Total Revenue | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Revenue Growth % | - | - | - |
| Non-Interest Expense | 28.46K | 1.06M | 835.76K |
| Efficiency Ratio | - | - | - |
| Operating Income | -28.46K▲ 0% | -1.06M▼ 3642.2% | -835.76K▲ 21.5% |
| Operating Margin % | - | - | - |
| Operating Income Growth % | - | -3642.23% | 21.52% |
| Pretax Income | 171.39K▲ 0% | 2.55M▲ 1389.0% | 1.06M▼ 58.5% |
| Pretax Margin % | - | - | - |
| Income Tax | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% |
| Net Income | 171.39K▲ 0% | 2.55M▲ 1389.0% | 1.06M▼ 58.5% |
| Net Margin % | - | - | - |
| Net Income Growth % | - | 1389.01% | -58.47% |
| Net Income (Continuing) | 171.39K | 2.55M | 1.06M |
| EPS (Diluted) | 0.02▲ 0% | 0.28▲ 1373.7% | 0.17▼ 39.3% |
| EPS Growth % | - | 1373.68% | -39.29% |
| EPS (Basic) | 0.02 | 0.28 | 0.17 |
| Diluted Shares Outstanding | 9.03M | 9.03M | 4.05M |
AFJK Balance Sheet
Aimei Health Technology Co., Ltd (AFJK) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|
| Cash & Short Term Investments | 580.72K | 28.21K | 2.93K |
| Cash & Due from Banks | 580.72K | 28.21K | 2.93K |
| Short Term Investments | 0 | 0 | 0 |
| Total Investments | 0 | 73.78M | 12.1M |
| Investments Growth % | - | - | -83.6% |
| Long-Term Investments | 0 | 73.78M | 12.1M |
| Accounts Receivables | 0 | 0 | 0 |
| Goodwill & Intangibles | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| PP&E (Net) | 0 | 0 | 0 |
| Other Assets | 69.89M | 0 | 0 |
| Total Current Assets | 580.72K | 30.38K | 2.93K |
| Total Non-Current Assets | 69.89M | 73.78M | 12.1M |
| Total Assets | 70.47M▲ 0% | 73.81M▲ 4.7% | 12.1M▼ 83.6% |
| Asset Growth % | - | 4.75% | -83.6% |
| Return on Assets (ROA) | 0.24% | 3.54% | 2.47% |
| Accounts Payable | 0 | 0 | 0 |
| Total Debt | 0 | 227.7K | 2.02M |
| Net Debt | -580.72K | 199.49K | 2.02M |
| Long-Term Debt | 0 | 0 | 0 |
| Short-Term Debt | 0 | 227.7K | 2.02M |
| Other Liabilities | 690K | 690K | 690K |
| Total Current Liabilities | 24.84K | 816.99K | 3.37M |
| Total Non-Current Liabilities | 690K | 690K | 690K |
| Total Liabilities | 714.84K | 1.51M | 4.06M |
| Total Equity | 69.76M▲ 0% | 72.31M▲ 3.7% | 8.04M▼ 88.9% |
| Equity Growth % | - | 3.66% | -88.88% |
| Equity / Assets (Capital Ratio) | 98.99% | 97.96% | 66.44% |
| Return on Equity (ROE) | 0.25% | 3.59% | 2.64% |
| Book Value per Share | 7.73 | 8.01 | 1.99 |
| Tangible BV per Share | 7.73 | 8.01 | 1.99 |
| Common Stock | 69.89M | 73.78M | 12.1M |
| Additional Paid-in Capital | 0 | 0 | 0 |
| Retained Earnings | -134.34K | -1.48M | -4.06M |
| Accumulated OCI | 0 | 0 | 0 |
| Treasury Stock | 0 | 0 | 0 |
| Preferred Stock | 0 | 0 | 0 |
AFJK Cash Flow Statement
Aimei Health Technology Co., Ltd (AFJK) cash flow — operating, investing & free cash flow history
| Line item | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|
| Cash from Operations | 0 | -672.29K | -565.1K |
| Operating CF Growth % | - | - | 15.94% |
| Net Income | 171.39K | 2.55M | 1.06M |
| Depreciation & Amortization | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 |
| Other Non-Cash Items | -196.23K | -3.62M | -1.62M |
| Working Capital Changes | 24.84K | 392.5K | 0 |
| Cash from Investing | -69.69M | -277.7K | 63.58M |
| Purchase of Investments | -69.69M | 0 | 0 |
| Sale/Maturity of Investments | 0 | 0 | 0 |
| Net Investment Activity | -69.69M | 0 | 0 |
| Acquisitions | 0 | 0 | 0 |
| Other Investing | 0 | -277.7K | 63.58M |
| Cash from Financing | 70.27M | 397.48K | -63.04M |
| Dividends Paid | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 |
| Stock Issued | 70.27M | 0 | 0 |
| Net Stock Activity | 70.27M | 0 | 0 |
| Debt Issuance (Net) | 0 | 277.7K | 0 |
| Other Financing | 0 | 119.78K | -63.04M |
| Net Change in Cash | 580.72K▲ 0% | -552.51K▼ 195.1% | -25.28K▲ 95.4% |
| Exchange Rate Effect | 0 | 0 | 0 |
| Cash at Beginning | 0 | 580.72K | 28.21K |
| Cash at End | 580.72K | 28.21K | 2.93K |
| Interest Paid | 0 | 0 | 0 |
| Income Taxes Paid | 0 | 0 | 0 |
| Free Cash Flow | 0▲ 0% | -672.29K▲ 0% | -565.1K▲ 15.9% |
| FCF Growth % | - | - | 15.94% |
AFJK Banking Ratios
Aimei Health Technology Co., Ltd (AFJK) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Return on Equity (ROE) | 0.25% | 3.59% | 2.64% |
| Return on Assets (ROA) | 0.24% | 3.54% | 2.47% |
| Net Interest Margin | 0.28% | 4.9% | 0% |
| Equity / Assets | 98.99% | 97.96% | 66.44% |
| Book Value / Share | 7.73 | 8.01 | 1.99 |
| NII Growth | - | 1709.88% | -100% |
AFJK SEC Filings & Documents
Aimei Health Technology Co., Ltd (AFJK) SEC filings — annual & quarterly reports (10-K, 10-Q)
AFJK Frequently Asked Questions
Aimei Health Technology Co., Ltd (AFJK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Aimei Health Technology Co., Ltd (AFJK) grew revenue by 0.0% over the past year. Growth has been modest.
Yes, Aimei Health Technology Co., Ltd (AFJK) is profitable, generating $1.1M in net income for fiscal year 2025.
Dividend & Returns
Aimei Health Technology Co., Ltd (AFJK) has a return on equity (ROE) of 2.6%. This is below average, suggesting room for improvement.
Industry Metrics
Aimei Health Technology Co., Ltd (AFJK) has a net interest margin (NIM) of N/A. NIM has been under pressure due to interest rate environment.
Aimei Health Technology Co., Ltd (AFJK) has an efficiency ratio of 0.0%. This is excellent, indicating strong cost control.
Explore More AFJK
Aimei Health Technology Co., Ltd (AFJK) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates